



## **ALX Oncology to Present at Jefferies 2019 Healthcare Conference**

May 31, 2019

DUBLIN, Ireland and BURLINGAME, Calif. – May 31, 2019 – ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 myeloid checkpoint mechanism, today announced that Jaume Pons, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 4:00 p.m. ET in New York, NY.

### **About ALX Oncology**

ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein comprised of an engineered high affinity CD47 binding domain of SIRP $\alpha$  linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to maximize the clinical benefit of antibody-based therapies and is in clinical development for a broad range of tumor types.

### **Contacts**

Karen Sharma  
MacDougall  
(781) 235-3060  
[alx@macbiocom.com](mailto:alx@macbiocom.com)